[go: up one dir, main page]

PE20191529A1 - Peptidos y metodos para el tratamiento de diabetes - Google Patents

Peptidos y metodos para el tratamiento de diabetes

Info

Publication number
PE20191529A1
PE20191529A1 PE2019001772A PE2019001772A PE20191529A1 PE 20191529 A1 PE20191529 A1 PE 20191529A1 PE 2019001772 A PE2019001772 A PE 2019001772A PE 2019001772 A PE2019001772 A PE 2019001772A PE 20191529 A1 PE20191529 A1 PE 20191529A1
Authority
PE
Peru
Prior art keywords
diabetes
treatment
peptides
methods
cst
Prior art date
Application number
PE2019001772A
Other languages
English (en)
Inventor
Elst Luc Vander
Vincent Carlier
Jean-Marie Saint-Remy
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of PE20191529A1 publication Critical patent/PE20191529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

Referido a un peptido inmunogenico aislado con una longitud de entre 12 y 50 aminoacidos, caracterizado porque comprende la secuencia Cxx[CST]SLQPLALEGSLQK [SEQ ID NO:4] O [CST]xxCSLQPLALEGSLQK [SEQ ID NO:5]. Tambien se refiere a un metodo in vitro para la generacion de una poblacion de celulas T CD4+ citoliticas contra APC que presenta epitopes de insulina. Este peptido se puede usar en el tratamiento o prevencion de diabetes tipo 1.
PE2019001772A 2017-03-09 2018-03-06 Peptidos y metodos para el tratamiento de diabetes PE20191529A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (1)

Publication Number Publication Date
PE20191529A1 true PE20191529A1 (es) 2019-10-23

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001772A PE20191529A1 (es) 2017-03-09 2018-03-06 Peptidos y metodos para el tratamiento de diabetes

Country Status (21)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CA (1) CA3051518A1 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
ES2584430T3 (es) * 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
PE20191529A1 (es) 2017-03-09 2019-10-23 Imcyse Sa Peptidos y metodos para el tratamiento de diabetes
CN114746111A (zh) * 2019-11-27 2022-07-12 易姆赛斯股份公司 用于对糖尿病患者进行分层的方法
JP2023525080A (ja) * 2020-05-06 2023-06-14 アンシス・エスア 新たな酸化還元酵素モチーフを有する免疫原性ペプチド
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
CN115916805A (zh) 2020-05-06 2023-04-04 易姆赛斯股份公司 具有延伸的氧化还原酶基序的免疫原性肽
CA3220752A1 (en) 2021-06-01 2022-12-08 Imcyse Sa Improved methods of treatment using immunogenic peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623391A1 (en) * 2005-09-22 2007-03-29 Yeda Research Development Co. Ltd. Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
ES2650236T3 (es) * 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
ES2584430T3 (es) 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
EP2623115A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP2249855B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation
AR081809A1 (es) 2010-03-29 2012-10-24 Inst Nat Sante Rech Med Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
MX2016005822A (es) 2013-11-04 2016-12-02 Uti Limited Partnership Metodos y composiciones para inmunoterpia sostenida.
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
PE20191529A1 (es) 2017-03-09 2019-10-23 Imcyse Sa Peptidos y metodos para el tratamiento de diabetes
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心

Also Published As

Publication number Publication date
KR20190126798A (ko) 2019-11-12
IL268874B1 (en) 2023-05-01
EP3592765A1 (en) 2020-01-15
CN110536898A (zh) 2019-12-03
WO2018162498A1 (en) 2018-09-13
ZA201905851B (en) 2021-04-28
CA3051518A1 (en) 2018-09-13
PH12019502036A1 (en) 2020-06-15
US20190352348A1 (en) 2019-11-21
CO2019009080A2 (es) 2019-08-30
AU2018229741A1 (en) 2019-08-15
RU2019126232A (ru) 2021-04-10
US20200407406A1 (en) 2020-12-31
CU24596B1 (es) 2022-05-11
IL268874A (en) 2019-10-31
BR112019018616A2 (pt) 2020-04-28
AU2018229741B2 (en) 2021-09-02
JP2020509067A (ja) 2020-03-26
IL268874B2 (en) 2023-09-01
RU2761653C2 (ru) 2021-12-13
JP2022125216A (ja) 2022-08-26
CN110536898B (zh) 2023-09-08
NZ755744A (en) 2023-07-28
US10808016B2 (en) 2020-10-20
US20220411476A1 (en) 2022-12-29
US11760782B2 (en) 2023-09-19
JP7102430B2 (ja) 2022-07-19
CU20190078A7 (es) 2020-04-02
MX2019010558A (es) 2019-10-21
SA519410007B1 (ar) 2023-02-16
MY192295A (en) 2022-08-17
AU2021277735A1 (en) 2021-12-23
SG11201908275XA (en) 2019-10-30
US11407795B2 (en) 2022-08-09
US20240092843A1 (en) 2024-03-21
RU2019126232A3 (es) 2021-06-01

Similar Documents

Publication Publication Date Title
PE20191529A1 (es) Peptidos y metodos para el tratamiento de diabetes
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
PE20180253A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer
PE20180487A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
AR069362A1 (es) Variantes de enzimas asparraginasas y sus usos
AR100238A1 (es) Método para producir l-aminoácidos en corinebacterias mediante el uso de un sistema de escisión de glicina
MX2018005063A (es) Polipéptidos condicionalmente activos.
MX2016002937A (es) Vacuna oncologica.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PE20191711A1 (es) Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
CL2018002495A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
PE20190628A1 (es) Nuevos peptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cancer
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
AR114790A1 (es) Producción de hidrocarburos
CY1118856T1 (el) Εμβολιο pcsk9
NZ765759A (en) Atf5 peptide variants and uses thereof